Study on Oxytocin's Effects on Trust and Learning in Healthy Children Using Nasal Spray
- Substances:Oxytocin
Belgium- Participants:0–17 years · Healthy volunteers
- Substances:Oxytocin
- Sponsor:UZ Leuven
Rare diseases
Investigational molecules
Locations
Back to Belgium2 059 clinical trials in Brussels, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
BelgiumStudy on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease
BelgiumStudy on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I
BelgiumLong-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis
BelgiumStudy on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma
BelgiumStudy on Doxycycline for Reducing Bacterial STIs in MSM and TGW with HIV
BelgiumStudy comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer
Belgium
BelgiumStudy Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
BelgiumStudy Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer
BelgiumStudy of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer
BelgiumStudy on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease
BelgiumThe busiest research cities in the country
What the registry says about research in the country
In Bruxelles, several trials focus on neoplasms, especially breast cancer, colorectal cancer, lung cancer, glioblastoma, soft tissue sarcoma, and other advanced solid tumors. These studies are designed to test new treatment combinations, improve survival outcomes, and refine more personalized care for people with difficult-to-treat cancers.
Much of this research aims to evaluate whether new therapeutic approaches can better control tumor growth and extend disease-free or overall survival.
Clinical trial activity in Bruxelles also includes nervous system diseases, with a strong focus on acute ischemic stroke and intracerebral haemorrhage. The main goal is to improve recovery after stroke and assess safer, more effective treatment strategies in urgent care settings.
These studies are centered on improving functional outcomes, supporting better reperfusion, and understanding how to optimize care after a stroke.
Research in respiratory tract diseases is active, particularly for pneumonia and severe infections requiring hospital or intensive care support. The trials are examining ways to reduce complications, improve recovery, and measure whether new add-on treatments can make standard care more effective.
This area includes efforts to test supportive treatments that may help improve survival and shorten the time patients spend in hospital.
Trials in cardiovascular diseases are studying conditions such as cardiogenic shock and other severe acute cardiac or circulatory emergencies. The research is focused on evaluating treatment effectiveness and safety in life-threatening situations where rapid decision-making is essential.
These studies aim to provide reliable evidence on outcomes such as mortality and time to hospital discharge.
A distinct group of studies addresses immune system diseases and virus diseases, with work on psoriasis, human papillomavirus, Epstein-Barr virus, and non genital warts. The research is designed to assess symptom improvement, infection clearance, and the longer-term safety of treatment options.
These trials reflect a mix of symptom-focused and infection-focused research in common yet persistent conditions.
Bruxelles is also hosting studies in bacterial infections and mycoses as well as chronic viral disease, including HIV. The emphasis is on improving clinical outcomes, supporting recovery, and testing therapies that may better control infection-related complications.
This area combines prevention, symptom control, and treatment-response research across several infection types.
Several trials are specifically focused on breast cancer, including early-stage, locally advanced, and metastatic disease. The research explores more individualized treatment strategies, including approaches guided by tumor biology and relapse risk.
These studies are intended to help match treatment intensity more closely to a patient’s risk profile and tumor characteristics.
Research in digestive system diseases includes studies of colon cancer and rectal cancer, with special attention to older adults and patients with higher recurrence risk. The main goal is to compare treatment strategies that may improve long-term cancer control.
This work explores how postoperative treatment choices can support better relapse-free survival and overall disease management.
Another research stream addresses longer-term treatment safety in immune system diseases, especially for chronic inflammatory conditions. In the city of Bruxelles, investigators are comparing whether newer therapies can maintain effectiveness while reducing health risks over time.
These trials are aimed at supporting safer long-term management for people living with chronic conditions.
Some trials cannot be neatly placed into a single therapeutic category, but they still contribute to the broader oncology and clinical research landscape. These studies often focus on evaluating new treatment options for patients with limited standard choices.
The common aim is to test whether emerging therapies can offer meaningful benefit where current options remain limited.
Tell us about your condition – we search every trial in Europe and connect you with the right site.